Sarepta Therapeutics, Inc. (SRPT) Earns Buy Rating from Robert W. Baird
A number of other analysts have also recently commented on SRPT. Needham & Company LLC lifted their target price on Sarepta Therapeutics from $47.00 to $81.00 and gave the stock a buy rating in a research report on Wednesday, September 14th. Oppenheimer Holdings, Inc. reiterated an outperform rating and set a $60.00 target price on shares of Sarepta Therapeutics in a research report on Wednesday, September 14th. SunTrust Banks, Inc. upgraded Sarepta Therapeutics from a reduce rating to a neutral rating in a research report on Wednesday, September 14th. Jefferies Group restated an underperform rating and issued a $7.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, September 15th. Finally, JMP Securities restated an underperform rating and issued a $10.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, September 15th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of Buy and an average price target of $60.06.
Sarepta Therapeutics (NASDAQ:SRPT) opened at 36.73 on Tuesday. The stock’s market cap is $2.01 billion. Sarepta Therapeutics has a 12 month low of $8.00 and a 12 month high of $63.73. The firm’s 50-day moving average price is $32.17 and its 200-day moving average price is $33.99.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Thursday, October 27th. The company reported ($0.95) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.32) by $0.37. During the same period last year, the firm posted ($1.25) EPS. On average, analysts predict that Sarepta Therapeutics will post ($5.15) earnings per share for the current year.
In related news, insider Sandesh Mahatme sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, October 17th. The stock was sold at an average price of $50.08, for a total value of $1,502,400.00. Following the sale, the insider now owns 61,532 shares of the company’s stock, valued at approximately $3,081,522.56. The transaction was disclosed in a filing with the SEC, which is available through this link. 10.90% of the stock is owned by corporate insiders.
A number of large investors have recently bought and sold shares of the stock. First Midwest Bank Trust Division raised its stake in Sarepta Therapeutics by 36.2% in the second quarter. First Midwest Bank Trust Division now owns 32,954 shares of the company’s stock worth $628,000 after buying an additional 8,754 shares during the last quarter. Emerald Mutual Fund Advisers Trust acquired a new position in shares of Sarepta Therapeutics during the second quarter worth $4,712,000. Emerald Advisers Inc. PA acquired a new position in shares of Sarepta Therapeutics during the second quarter worth $4,491,000. Quantitative Systematic Strategies LLC acquired a new position in shares of Sarepta Therapeutics during the second quarter worth $211,000. Finally, Bank of New York Mellon Corp raised its position in shares of Sarepta Therapeutics by 1.0% in the second quarter. Bank of New York Mellon Corp now owns 221,818 shares of the company’s stock worth $4,231,000 after buying an additional 2,282 shares in the last quarter. 76.99% of the stock is currently owned by hedge funds and other institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.